Prothena Corp PLC (PRTA)

65.05
NASDAQ : Health Care
Prev Close 65.05
Day Low/High 0.00 / 0.00
52 Wk Low/High 40.58 / 69.53
Avg Volume 277.60K
Exchange NASDAQ
Shares Outstanding 38.28M
Market Cap 2.50B
EPS -4.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Six charts showing signs of smart money footprints.

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

First-In-Human Assessment Of PRX002, Prothena's Anti-Alpha Synuclein Antibody For Parkinson's Disease, Published In Movement Disorders Journal

Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders

TheStreet Quant Rating: D (Sell)